# TCGX

> TCGX, also known as TCG Crossover, is a science-driven biotech investment firm founded by Chen Yu in 2021. It uses closed-end funds to invest across private and public drug developers and supports portfolio companies with scientific diligence, financing strategy and operational advice. Its flagship funds focus on the United States and Europe; a separate $600 million Asia fund closed in October 2026.

- **Founded:** 2021
- **Headquarters:** Palo Alto, United States
- **Founders:** Chen Yu (Founder and Managing Partner)
- **Products:** Flagship biotech investment funds, Portfolio company support, TCGX Asia Life Sciences Fund I
- **Notable:** Closed an $824 million debut fund announced in April 2021., Closed $1 billion Fund II in January 2024, exceeding its original $900 million hard cap., Closed $1.3 billion Fund III in October 2025, taking announced aggregate capital raised above $3.1 billion at that date.

## Products & services

- **Flagship biotech investment funds** — Closed-end funds investing across private and public biotechnology companies, with current flagship geographic focus on the United States and Europe.
- **Portfolio company support** — Scientific and pipeline diligence, capital markets guidance, geographic expansion support and access to scientific advisors and operating executives.
- **TCGX Asia Life Sciences Fund I** — Separate $600 million vehicle for Asia-based biotechnology companies across development stages, announced with offices in Shanghai and Hong Kong.

## Achievements

- Closed an $824 million debut fund announced in April 2021.
- Closed $1 billion Fund II in January 2024, exceeding its original $900 million hard cap.
- Closed $1.3 billion Fund III in October 2025, taking announced aggregate capital raised above $3.1 billion at that date.
- Led Abivax’s EUR 130 million February 2023 financing.
- Added a separate $600 million Asia-focused fund in October 2026.

## Latest updates

- **2026-10** — Announced the closing of the oversubscribed $600 million TCGX Asia Life Sciences Fund I on October 7, with new offices in Shanghai and Hong Kong; the vehicle operates separately from its US/Europe flagship funds.
- **2026-09** — A September SEC prospectus for an affiliated acquisition company reported approximately $5.1 billion in TCGX regulatory assets under management as of December 31, 2025. Regulatory AUM is distinct from cumulative capital raised.
- **2025-10** — Closed $1.3 billion Fund III and promoted Giuliano Marostica to Managing Partner.

## Links

- Website: https://tcgcrossover.com/
- LinkedIn: https://www.linkedin.com/company/tcg-crossover/

---

Profile page: https://yespress.io/tcgx
Published by YesPress — https://yespress.io
Last updated: 2026-10-27